Smooth muscle relaxants used for relief GI and UG spasms. Drugs influencing uterus functions. Antihistamines H1-blocker Flashcards
Agents used
papaverine.
drotaverine. butylscopolamine. misoprostol.
oxytocin.
ergotamine.
terbutaline.
atosiban.
Mg++.
ethanol .
solifenacin.
oxybutinine.
tamsulosin.
Histamine
Organic, nitrogen-containing compound; classified as amine autacoid (physiologically active metabolite, released by specific cells and tissues, having short-lasting and local effects)
▪ Cells with histamine synthesis and storage properties
- CNS neurons (role in sleep-arousal regulation)
- Enterochromaffin cells
- Mast cells
- Basophils, eosinophils
H1
H1
Smooth muscle
Endothelium
Brain
Gq
- Capillary dilation (via NO) → BP ↓
- Capillary permeability → tissue edema
- Bronchiolar smooth muscle contraction
(bronchoconstriction) - Activation of peripheral nociceptive
receptors → pain and pruritus - Nasal and bronchial mucous secretion ↑
H2
H2
Gastric mucosa
Cardiac muscle
Mast cells
Brain
Gs
- Gastric acid secretion ↑
- Cardiac stimulant effect: SA nodal rate
and automaticity ↑, positive inotropic - Negative feedback effect – reduce
histamine release from mast cells
H3
H3
Presynaptic receptors in the CNS and periphery
Gi
- Presynaptic modulation of histaminergic neurons in the CNS and the periphery
H4
H4
Eosinophils
Neutrophils
CD4+ T-cells
Gi
- Chemotactic response in leukocyte (especially eosinophils) and mast cells
Antihistamines
H1 receptor antagonists – 1st gen’:
Diphenhydramine
Promethazine
Dimetindene
H1 receptor antagonists – 2nd gen’
Cetirizine
Loratadine
Fexofenadine
H2 receptor antagonists Cimetidine Ranitidine Famotidine Nizatidine
H1 receptor antagonists – 1st gen’
- Competitive inhibitors of central and peripheral H1 receptors
- α-adrenergic receptor inhibition properties
- M-cholinergic receptor inhibition properties
- Serotonin receptor inhibition properties (only a few agents)
Diphenhydramine
Promethazine
Dimetindene
Diphenhydramine
H1 receptor antagonists – 1st gen’
- Competitive inhibitors of central and peripheral H1 receptors
- α-adrenergic receptor inhibition properties
- M-cholinergic receptor inhibition properties
- Serotonin receptor inhibition properties (only a few agents)
- Oral or parenteral
- Duration of action 4-12 h’
- Metabolism by hepatic CYP450
(affected by drugs that induce/inhibit hepatic metabolism) - Lipophilic (easily cross the blood-brain-barrier)
- IgE-mediated allergies (ex. hay fever, urticaria)
- Sedative (ex. preoperative sedation)
- Antiemetic (ex. chemotherapy-induced vomiting)
- Sleep-aid formulations (over the counter drug)
- Anti-motion sickness
- Control of nausea and vomiting of pregnancy
(in combination with pyridoxine - B6 vitamin) - Management of acute extrapyramidal symptoms
(ex. due to antipsychotics) - Side effects: sedation, antimuscarinic effects
(dry mouth, blurred vision, glaucoma exacerbation), α-adrenoreceptor inhibitory effects (orthostatic hypotension) - Interactions: additive sedation with other sedatives (BZD, alcohol)
Promethazine
H1 receptor antagonists – 1st gen’
- Competitive inhibitors of central and peripheral H1 receptors
- α-adrenergic receptor inhibition properties
- M-cholinergic receptor inhibition properties
- Serotonin receptor inhibition properties (only a few agents)
- Oral or parenteral
- Duration of action 4-12 h’
- Metabolism by hepatic CYP450
(affected by drugs that induce/inhibit hepatic metabolism) - Lipophilic (easily cross the blood-brain-barrier)
- Less anti-motion sickness effect
- More sedative and autonomic effects
Dimetindene
H1 receptor antagonists – 1st gen’
- Competitive inhibitors of central and peripheral H1 receptors
- α-adrenergic receptor inhibition properties
- M-cholinergic receptor inhibition properties
- Serotonin receptor inhibition properties (only a few agents)
- Oral or parenteral
- Duration of action 4-12 h’
- Metabolism by hepatic CYP450
(affected by drugs that induce/inhibit hepatic metabolism) - Lipophilic (easily cross the blood-brain-barrier)
- Symptomatic treatment of allergic reactions
- Minimally crosses blood-brain-barrier → milder side
effects with efficient control of allergies
H1 receptor antagonists – 2nd gen’
- Competitive inhibitors of peripheral H1 receptors
- No autonomic or anti-motion sickness effect
Cetirizine
Loratadine
Fexofenadine
- IgE-mediated allergies (hay fever, urticaria, angioedema)
- Side effects (generally milder compared to 1st gen’): sedation, arrhythmias in overdose
- Interactions: additive sedation with other sedatives (BZD, alcohol)
- Much less lipophilic (less likely to cross the blood-brain-barrier)
Cetirizine
H1 receptor antagonists – 2nd gen’
- Competitive inhibitors of peripheral H1 receptors
- No autonomic or anti-motion sickness effect
- Oral or parenteral
- Duration of action 12-24 h’
- Metabolism by hepatic CYP450
(affected by drugs that induce/inhibit hepatic metabolism) - Much less lipophilic (less likely to cross the blood-brain-barrier)
- IgE-mediated allergies (hay fever, urticaria, angioedema)
- Side effects (generally milder compared to 1st gen’): sedation, arrhythmias in overdose
- Interactions: additive sedation with other sedatives (BZD, alcohol)
Loratadine
H1 receptor antagonists – 2nd gen’
- Competitive inhibitors of peripheral H1 receptors
- No autonomic or anti-motion sickness effect
- Oral or parenteral
- Duration of action 12-24 h’
- Metabolism by hepatic CYP450
(affected by drugs that induce/inhibit hepatic metabolism) - Much less lipophilic (less likely to cross the blood-brain-barrier)
- IgE-mediated allergies (hay fever, urticaria, angioedema)
- Side effects (generally milder compared to 1st gen’): sedation, arrhythmias in overdose
- Interactions: additive sedation with other sedatives (BZD, alcohol)
Fexofenadine
H1 receptor antagonists – 2nd gen’
- Competitive inhibitors of peripheral H1 receptors
- No autonomic or anti-motion sickness effect
- Oral or parenteral
- Duration of action 12-24 h’
- Metabolism by hepatic CYP450
(affected by drugs that induce/inhibit hepatic metabolism) - Much less lipophilic (less likely to cross the blood-brain-barrier)
- IgE-mediated allergies (hay fever, urticaria, angioedema)
- Side effects (generally milder compared to 1st gen’): sedation, arrhythmias in overdose
- Interactions: additive sedation with other sedatives (BZD, alcohol)
H2 receptor antagonists
- Competitive inhibitors of peripheral H2 receptors
- No H1, autonomic or anti-motion sickness effects
Cimetidine
Ranitidine
Famotidine
Nizatidine
Cimetidine
H2 receptor antagonists
- Competitive inhibitors of peripheral H2 receptors
- No H1, autonomic or anti-motion sickness effects
- Oral or parenteral
- Duration of action 12-24 h’
- Metabolism by hepatic CYP450
(affected by drugs that induce/inhibit hepatic metabolism) - Acid peptic disease (duodenal and gastric)
- Control of Zollinger-Allison syndrome (gastrin-secreting
neuroendocrine tumor) - Gastroesophageal reflux disease (GERD)
- Stress ulcers, mucosal erosion, gastric hemorrhage in
ICU patients (given IV) - Not 1st-line agent in the reduction of gastric acidity! (initial approach is based on treatment with PPI’s)
- Side effects: cimetidine (but not other agents) is a weak antiandrogenic agent and a potent P450 enzyme inhibitor
Ranitidine
H2 receptor antagonists
- Competitive inhibitors of peripheral H2 receptors
- No H1, autonomic or anti-motion sickness effects
- Oral or parenteral
- Duration of action 12-24 h’
- Metabolism by hepatic CYP450
(affected by drugs that induce/inhibit hepatic metabolism) - Acid peptic disease (duodenal and gastric)
- Control of Zollinger-Allison syndrome (gastrin-secreting
neuroendocrine tumor) - Gastroesophageal reflux disease (GERD)
- Stress ulcers, mucosal erosion, gastric hemorrhage in
ICU patients (given IV) - Not 1st-line agent in the reduction of gastric acidity! (initial approach is based on treatment with PPI’s)
- Side effects: cimetidine (but not other agents) is a weak antiandrogenic agent and a potent P450 enzyme inhibitor
Famotidine
H2 receptor antagonists
- Competitive inhibitors of peripheral H2 receptors
- No H1, autonomic or anti-motion sickness effects
- Oral or parenteral
- Duration of action 12-24 h’
- Metabolism by hepatic CYP450
(affected by drugs that induce/inhibit hepatic metabolism) - Acid peptic disease (duodenal and gastric)
- Control of Zollinger-Allison syndrome (gastrin-secreting
neuroendocrine tumor) - Gastroesophageal reflux disease (GERD)
- Stress ulcers, mucosal erosion, gastric hemorrhage in
ICU patients (given IV) - Not 1st-line agent in the reduction of gastric acidity! (initial approach is based on treatment with PPI’s)
- Side effects: cimetidine (but not other agents) is a weak antiandrogenic agent and a potent P450 enzyme inhibitor
Nizatidine
H2 receptor antagonists
- Competitive inhibitors of peripheral H2 receptors
- No H1, autonomic or anti-motion sickness effects
- Oral or parenteral
- Duration of action 12-24 h’
- Metabolism by hepatic CYP450
(affected by drugs that induce/inhibit hepatic metabolism) - Acid peptic disease (duodenal and gastric)
- Control of Zollinger-Allison syndrome (gastrin-secreting
neuroendocrine tumor) - Gastroesophageal reflux disease (GERD)
- Stress ulcers, mucosal erosion, gastric hemorrhage in
ICU patients (given IV) - Not 1st-line agent in the reduction of gastric acidity! (initial approach is based on treatment with PPI’s)
- Side effects: cimetidine (but not other agents) is a weak antiandrogenic agent and a potent P450 enzyme inhibitor
Eicosanoid agonists
Misoprostol Alprostadil Dinoprostone Carboprost Latanoprost Epoprostenol